Frank Ruschitzka MD FESC FRCP Shares Some Thoughts on the Future Direction of the Heart Failure Association of the European Society of Cardiology
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Dossier post-publication
OpenAlex signale ce travail comme rétracté, mais aucune notice correspondante de Retraction Watch ne figure dans cette base.
Résumé
AIMS: The left atrial appendage (LAA) produces natriuretic peptides and its removal or occlusion might increase the risk of heart failure (HF). We aimed to investigate the incidence of HF after LAA occlusion or removal (LAAO) in the Left Atrial Appendage Occlusion Study (LAAOS III). METHODS AND RESULTS: -VASc score ≥2, who were having cardiac surgery for another indication, were randomized to undergo surgical LAAO or not. We compared the composite outcome of HF-related hospitalizations and HF death between the two groups. HF assessment required clinical and radiographic evidence of HF. Analyses included a landmark analysis before and after 30 days and subgroups. Mean age was 71.2 years, 67.5% were male and 57.0% had prior HF. Over a mean follow-up of 3.8 years, 396 (8.3%) patients met the composite HF outcome: 209 (8.8%) with LAAO (n = 2379) and 187 (7.8%) without LAAO (n = 2391) (hazard ratio [HR] 1.12, 95% confidence interval [CI] 0.92-1.37, p = 0.25). There was no difference between the two groups in the first 30 days (1.6% vs. 1.1%; p = 0.12) and thereafter (7.6% vs. 7.1%; p = 0.57). Subgroups based on age, sex, body mass index, AF type, prior HF, cardiac rhythm or left ventricular ejection fraction showed consistent results. There was no difference in HF outcomes with LAAO between the cut-and-sew (HR 0.93, 95% CI 0.70-1.23, p = 0.62) versus other closure methods (HR 1.05, 95% CI 0.77-1.41, p = 0.77). CONCLUSIONS: Left atrial appendage occlusion or removal at the time of cardiac surgery does not appear to alter the risk of HF-related hospitalization or death. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01561651.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- European Journal of Heart Failure
- Thématique
- Atrial Fibrillation Management and Outcomes
- Domaine
- Medicine
- Établissements canadiens
- Hamilton Health SciencesMcMaster UniversityPopulation Health Research Institute
- Organismes subventionnaires
- Biosense WebsterCanadian Institutes of Health ResearchCytoSorbents EuropeServierFondazione Internazionale MenariniBoston Scientific CorporationSvenska Sällskapet för Medicinsk ForskningPfizerHeart and Stroke Foundation of CanadaVetenskapsrådetEli Lilly and CompanyAstraZenecaAtriCureFoundation for Cardiovascular ResearchMcMaster UniversitySchweizerische Herzstiftung
- Mots-clés
- MedicineHeart failureAssociation (psychology)CardiologyInternal medicinePsychologyPsychotherapist
- Résumé présent dans OpenAlex
- oui